Computed tomography angiography (CTA) revealed consecutive saccular aneurysms (11x9 mm, 21x13 mm, and 27x17 mm) extending to the hilar region on the main left renal artery (Figures 1a, b). All of the segmental arteries originated from the aneurysms, and stenotic segments were also present between the aneurysms. In addition, an accessory renal artery and a parapelvic cyst measuring 48x63 mm were also present. No dilation of the renal collecting system or urinary tract stones were detected.
Endovascular treatment was preferable to surgery because of the solitary kidney, the location of the saccular aneurysms, and the originating point of the segmental renal arteries. The options of a covered stent or coil embolization were not considered due to the wide-necked aneurysms and the origin of segmental arteries. We decided to use the MFM® stent because we intended to exclude the aneurysms from the vascular system and preserve the segmental arteries.
The patient was given clopidogrel (75 mg) and acetylsalicylic acid (300 mg) for 10 days prior to the procedure. The right brachial artery was cannulated under ultrasound guidance with a 6 French (F) 90 cm guiding sheath (Cook Medical Inc., Bloomington, IN, USA) and then advanced to the abdominal aorta. Meanwhile, an IV bolus of heparin (5000 IU) was also administered. The proximal part of the renal artery was catheterized with a 5F headhunter catheter (Boston Scientific-Heridia, La Aurora, Heredia, Costa Rica) and a 0.035-inch Radifocus® Glidewire Advantage peripheral guide wire (Terumo Europe N.V., Leuven, Belgium) via the guiding sheath. Next, a Progreat 2.7F coaxial micro catheter system (Terumo Europe N.V., Leuven, Belgium) was used to pass the aneurysmal segments through the headhunter catheter. After inserting a long, stiff Hi-Torque Steelcore 0.018-inch peripheral guide wire (Abbott Vascular Inc., Santa Clara, CA, USA), the 10x80 mm MFM® stent was inserted through the renal artery to cover all of the aneurysms (Figures 2a, b). The patient was then discharged without any complications on the same day with dual antiplatelet therapy (300 mg acetylsalicylic acid and 75 mg clopidogrel).
The first-, six-, and 12-month follow-up CTA showed no changes in the aneurysms. The proximal and distal aneurysms were thrombosed, but the aneurysm in the middle had a 6 mm residual enhancement (Figures 3a, b). The stent patency was intact, and no intimal hyperplasia or loss in the segmental branches originating from the aneurysms was detected. Although focal cortical loss of the renal parenchyma distal to the stent was noted, no renal function loss was seen after the procedure. At the one-year follow-up, the patients flank pain had completely resolved.
Fibromuscular dysplasia is an idiopathic event caused by the hypertrophy of fibrous and muscular elements of the arterial media and adventitia leading to stenosis. It is thought to be related to aneurysms as well as spontaneous arterial dissection. This type of dysplasia often involves the medial part of renal arteries and does not contain calcifications. Furthermore, the aneurysms originating from fibromuscular dysplasia accompanied by stenosis are chaplet-like in appearance and are usually seen in women.[6] Although radiological images might indicate the etiology, the final diagnosis is made via a histopathological evaluation. Our patient was also female and had chaplet-like aneurysms located in the medial part of the renal artery accompanied by stenotic segments. Moreover, no calcification was noted; therefore, we believe that the underlying cause of the RAA was fibromuscular dysplasia.
Renal artery aneurysms are usually asymptomatic, but HT, flank pain, and hematuria can be seen in symptomatic patients, with the most common finding (90%) being HT.[7] Renal artery thrombosis, secondary infarction to the distal emboli, arteriovenous fistula formation, and rupture are among the complications associated with RAAs. Rupture is feared the most because of its fatal consequences (nearly 80% mortality rate).[8] Males and postmenopausal women have a low risk of rupture, whereas women in the third trimester of pregnancy have a very high risk. Furthermore, fusiform and calcified aneurysms have a lower risk of rupture, whereas non-calcified and saccular aneurysms have a higher risk. For all aneurysms, a greater RAA diameter increases the risk of rupture, but this is especially true for those larger than 2 cm in diameter.[6]
Henke et al.[9] recommended treatment for RAAs measuring ≥1 cm accompanied by uncontrolled HT, all RAAs >2 cm, and most RAAs with a diameter of between 1.5-2 cm. The most important indications are uncontrolled HT and female gender, but flank pain, distal emboli, and pregnancy should also be kept in mind.[3] Among the treatment indications for our patient were the saccular form of the RAA, its large diameter, and the absence of calcification. Additionally, the patient was female and had flank pain.
Surgical treatment includes resection of the aneurysm, an aortorenal bypass, renorenal graft interposition, and patch angioplasty.[3] In their surgical series, Dzsinich et al.[10] reported t hat HT was treated in between 50-88% of their cases and that successful preservation of segmental branches occurred in 86%. Surgical complications may include branch occlusion, uretheral stenosis, postoperative graft occlusion, the need for a nephrectomy, and death.[5] The various surgical methods for treating RAAs are technically difficult and require a retroperitoneal dissection, which has a 28% morbidity rate. Therefore, these risks make endovascular treatment a strong alternative to other surgical options.[5]
There are various endovascular treatment methods, including stent-graft placement, coil embolization with or without a balloon or stent, and glue or onyx embolization to separate the aneurysm from arterial circulation. However, these techniques may be technically difficult to perform since side branches may originate from the wide-necked aneurysm, as was the case with our patient. This complication can then lead to a significant loss of renal parenchyma.[3,5]
Due to such conditions, new endovascular treatment methods, such as the MFM® stent should be considered. This stent (Figure 4) is composed of a three-dimensional, interlocked, porous system which cannot prevent the blood flow from entering the aneurysmal sac. However, the flow velocity within the aneurysmal sac is reduced, thus causing an organized thrombus to form in the sac, due to the hemodynamic flow-modulating effect. When this occurs, there is little or difficult supply with blood collateral circulation and multilayer stenting allows the collateral circulation to be correctly supplied, promoting a more regular flow. Finally, with the MFM®, the turbulent flow caused by the aneurysm is reversed and becomes laminar in nature, thus excluding the aneurysm from the circulation but preserving the flow into the side branches.[11-13]
We treated our patient with this specifically designed stent, and after one year of follow-up, no loss in renal function was detected, and the patients flank pain disappeared. In addition, two of the aneurysms were completely thrombosed, and the third was substantially thrombosed. Furthermore, no changes in the diameter of the aneurysms were seen during the follow-up.
Declaration of conflicting interests
The authors declared no conflicts of interest with
respect to the authorship and/or publication of this
article.
Funding
The authors received no financial support for the
research and/or authorship of this article.
1) Stanley JC, Rhodes EL, Gewertz BL, Chang CY, Walter
JF, Fry WJ. Renal artery aneurysms. Significance of
macroaneurysms exclusive of dissections and fibrodysplastic
mural dilations. Arch Surg 1975;110:1327-33.
2) Porcaro AB, Migliorini F, Pianon R, Antoniolli SZ, Furlan F,
De Biase V, et al. Intraparenchymal renal artery aneurysms.
Case report with review and update of the literature. Int Urol
Nephrol 2004;36:409-16.
3) Rundback JH, Rizvi A, Rozenblit GN, Poplausky M,
Maddineni S, Crea G, et al. Percutaneous stent-graft
management of renal artery aneurysms. J Vasc Interv Radiol
2000;11:1189-93.
4) Lumsden AB, Salam TA, Walton KG. Renal artery aneurysm:
a report of 28 cases. Cardiovasc Surg 1996;4:185-9.
5) Tan WA, Chough S, Saito J, Wholey MH, Eles G. Covered
stent for renal artery aneurysm. Catheter Cardiovasc Interv
2001;52:106-9.
6) Trambert JJ. Vascular manifestation of renal disease. In:
Bakal CW, Silberzweig JE, Cynamon J, Sprayregen S,
editors. Vascular and interventional radiology: principles
and practices. 1st ed. New York: Thieme Medical Publishers;
2002. p. 267-85.
7) Bulbul MA, Farrow GA. Renal artery aneurysms. Urology
1992;40:124-6.
8) Tham G, Ekelund L, Herrlin K, Lindstedt EL, Olin T,
Bergentz SE. Renal artery aneurysms. Natural history and
prognosis. Ann Surg 1983;197:348-52.
9) Henke PK, Cardneau JD, Welling TH 3rd, Upchurch GR Jr.
Wakefield TW, Jacobs LA, et al. Renal artery aneurysms.
a 35-year clinical experience with 252 aneurysms in 168
Patients. Ann Surg 2001;234:454-63.
10) Dzsinich C, Gloviczki P, McKusick MA, Pairolero PC,
Bower TC, Hallett JW Jr, et al. Surgical management of renal
artery aneurysm. Cardiovasc Surg 1993;1:243-7.
11) Henry M, Polydorou A, Frid N, Gruffaz P, Cavet A, Henry I,
et al. Treatment of renal artery aneurysm with the multilayer
stent. J Endovasc Ther 2008;15:231-6.